induc
high
level
antibodi
produc
system
local
immun
mlvvaccin
amervac
porcili
produc
suffici
antibodi
level
also
cellmedi
immun
infect
viru
secret
gradual
decreas
group
indic
tendenc
induc
steril
immun
goal
studi
compar
immun
respons
differ
kill
modifi
live
vaccin
prr
viru
monitor
antibodi
product
cell
mediat
immun
system
local
level
experi
immun
four
group
piglet
two
commerci
inactiv
two
modifi
live
vaccin
twentyon
day
final
vaccin
piglet
includ
control
nonimmun
group
infect
lelystad
strain
prr
viru
serum
antibodi
respons
igm
igg
strongest
group
follow
two
mlv
group
local
demonstr
highest
level
igg
antibodi
bronchoalveolar
lavag
balf
saliva
group
wherea
low
iga
antibodi
respons
balf
fece
detect
group
found
viru
neutral
antibodi
dpv
day
post
vaccin
higher
level
group
includ
control
dpi
day
post
infect
posit
antigen
specif
cellmedi
respons
lymphocyt
transform
test
ltt
observ
group
dpv
group
dpv
interv
infect
produc
lymphocyt
antigen
stimul
found
subset
immun
group
day
infect
infect
obviou
differ
viru
excret
viru
detect
group
piglet
serum
saliva
occasion
fece
dpi
significantli
lower
viru
load
found
group
dpi
neg
sampl
appear
dpi
group
saliva
conclud
antibodi
immun
infect
viru
infect
detect
compart
monitor
immun
inactiv
vaccin
porcin
reproduct
respiratori
syndrom
prr
econom
signific
infecti
diseas
current
affect
swine
worldwid
typic
clinic
symptom
prr
mild
sever
respiratori
diseas
infect
newborn
grow
pig
reproduct
failur
pregnant
sow
two
genotyp
prr
viru
prrsv
identifi
european
type
north
american
type
consider
genet
virul
differ
within
prrsv
genotyp
correl
lack
crossprotect
vaccin
highli
pathogen
strain
prrsv
hpprrsv
identifi
within
genotyp
depend
viral
strain
immun
statu
host
swine
farm
may
pig
subclin
infect
wherea
other
experi
sever
reproduct
andor
respiratori
diseas
infect
classic
highli
pathogen
strain
associ
aberr
host
immun
respons
swine
known
natur
host
prrsv
primari
target
cell
replic
prrsv
porcin
alveolar
macrophag
pam
first
stage
repres
acut
infect
result
viremia
h
postinfect
pi
last
sever
week
despit
presenc
circul
antibodi
second
persist
stage
infect
viru
longer
detect
blood
lung
pig
longer
exhibit
sign
clinic
diseas
stage
viral
replic
primarili
local
lymphoid
organ
includ
tonsil
lymph
node
infect
prrsv
elicit
poor
innat
adapt
immun
respons
associ
immun
modul
incomplet
viral
clearanc
pig
depend
age
immun
statu
infect
certain
prrsv
strain
induc
signific
suppress
nk
cell
cytotox
activ
quantiti
proinflammatori
cytokin
significantli
lower
viral
infect
strain
depend
prrsv
also
poor
induc
infect
prrsv
induc
antibodi
respons
product
dpi
evid
protect
prrsv
infect
serum
neutral
antibodi
appear
later
typic
day
pi
viru
also
evad
host
cellmedi
immun
like
promot
immunosuppress
cytokin
result
delay
onset
immun
respons
similarli
immunosuppress
function
prrsv
shown
probabl
mediat
cytokin
action
treg
immunosuppress
induc
prrsv
facilit
viral
bacteri
infect
vaccin
princip
mean
use
control
treat
prrsv
infect
sever
comprehens
review
articl
publish
recent
critic
evalu
differ
vaccin
approach
prr
viru
indic
main
weak
current
vaccin
vaccin
strategi
among
other
problem
caus
high
heterogen
occurr
highli
pathogen
strain
therefor
effort
made
develop
vaccin
broad
spectrum
effect
howev
opinion
still
prevail
vaccin
costbenefici
health
intervent
studi
follow
three
aim
establish
complex
immun
respons
characterist
use
sever
methodolog
approach
monitor
dynam
differ
compart
timedepend
manner
vaccin
challeng
infect
compar
type
immun
respons
vaccin
inactiv
live
attenu
vaccin
subsequ
challeng
use
homolog
strain
twentyf
wean
piglet
age
week
weigh
kg
larg
white
breed
prrsv
neg
herd
use
neg
statu
anim
confirm
serolog
use
commerci
elisa
kit
idexx
lab
use
anim
approv
branch
commiss
anim
welfar
ministri
agricultur
czech
republ
approv
protocol
part
project
part
project
respig
four
commerci
vaccin
use
characterist
tabl
viru
clarifi
centrifug
concentr
determin
plaqu
assay
concentr
stock
viru
use
experi
plaqu
form
unit
per
ml
twentyf
piglet
use
experi
piglet
assign
five
group
five
anim
accord
weight
gender
anim
hous
isol
room
keep
anim
one
experiment
group
room
anim
left
acclim
day
stock
piglet
clinic
healthi
time
experi
start
day
two
group
piglet
immun
anim
administ
ml
inactiv
vaccin
intramuscular
im
inject
day
piglet
group
revaccin
dose
piglet
two
group
immun
ml
mlv
vaccin
health
statu
piglet
monitor
regular
basi
includ
temperatur
measur
sampl
blood
bodi
fluid
taken
respect
examin
preset
time
interv
addit
day
pig
includ
control
group
infect
ml
live
prr
viru
piglet
monitor
anoth
day
slaughter
euthanasia
perform
exsanguin
combin
anesthesia
tkx
telazolketaminxylazin
mixtur
contain
mgml
tiletamin
mgml
zolazepam
telazol
virbac
carro
franc
mgml
ketamin
vetoquinol
lure
franc
mgml
xylazin
bioveta
ivanovic
na
hane
czech
republ
administ
intramuscularli
final
volum
mlkg
bodi
weight
well
collect
blood
bodi
fluid
intestin
content
bronchoalveolar
lavag
autopsi
perform
organ
lung
parenchyma
spleen
lymph
node
collect
virolog
examin
blood
sampl
serum
heparintr
blood
sampl
taken
jugular
vein
group
salin
sampl
collect
use
rope
left
hutch
h
individu
fecal
sampl
collect
handl
anim
bronchoalveolar
lavag
fluid
balf
sampl
perform
first
time
live
anim
second
time
slaughter
intravit
lavag
perform
anim
gener
anesthesia
mixtur
xylazin
ketamin
without
use
endoscop
method
describ
earlier
pig
posit
sternal
recumb
endotrach
tube
insert
trachea
ml
steril
pb
ph
inject
distal
part
airway
toward
bronchu
infus
salin
recov
balf
aspir
filter
centrifug
min
g
supernat
store
c
prior
serolog
analys
total
rna
experiment
sampl
sera
oral
fluid
bal
extract
use
nucleospin
r
rna
ii
kit
machereynagel
accord
manufactur
instruct
protocol
total
rna
prepar
biolog
fluid
rna
obtain
elut
rnasefre
water
immedi
use
qrtpcr
amplif
remain
rna
frozen
c
subsequ
use
isol
rna
use
qrtpcr
amplif
ezprrsv
tm
mpx
real
time
rtpcr
kit
tetracor
accord
manufactur
instruct
quantif
viru
genom
copi
base
quantif
standard
includ
kit
evalu
system
local
antibodi
product
two
elisa
method
use
swine
sera
test
examin
commerci
avail
elisa
test
ingezim
prr
univers
ingenasa
accord
manufactur
instruct
examin
presenc
n
protein
specif
igg
antibodi
swine
sera
oral
fluid
bal
test
examin
homemad
indirect
elisa
test
base
recombin
nucleocapsid
protein
n
prr
viru
develop
previous
depart
detect
specif
igm
igg
iga
antibodi
optim
antigen
serum
antibodi
concentr
determin
checkerboard
titrat
posit
neg
porcin
sera
cutoff
valu
determin
defin
upper
predict
limit
base
upper
tail
tdistribut
neg
control
od
read
confid
level
posit
serum
absorb
correspond
calcul
cutoff
includ
test
plate
recombin
n
protein
dilut
mm
bicarbonatecarbon
buffer
ph
final
concentr
coat
plate
maxisorp
ii
r
immunopl
nunc
denmark
overnight
c
well
block
skim
milk
pb
min
c
wash
pb
posit
neg
control
includ
test
plate
sampl
dilut
skim
milk
tpb
pb
tween
nacl
ad
duplic
antigenco
well
differ
among
differ
type
sampl
one
hundr
microlit
serum
sampl
dilut
detect
igm
antibodi
nondilut
sampl
bal
detect
igg
iga
antibodi
incub
min
c
two
hundr
fifti
microlit
oral
fluid
dilut
incub
h
c
detect
igg
antibodi
subsequ
plate
wash
three
time
tpb
antibodi
bind
detect
incub
min
c
antipig
igm
peroxidas
conjug
bethyl
antipig
igg
peroxidas
conjug
sigma
antipig
iga
peroxidas
conjug
bethyl
separ
dilut
tpb
skim
milk
wash
plate
describ
per
well
tmbcomplet
testlin
substrat
ad
optic
densiti
od
measur
nm
incub
time
min
room
temperatur
viru
neutral
test
detect
prrsv
neutral
antibodi
perform
follow
sampl
sera
dilut
dmem
medium
sigmaaldrich
supplement
fb
heat
inactiv
sera
c
min
dilut
serial
flatbottom
nunc
next
equal
volum
media
contain
prrsv
pfu
lelystadcapm
ad
well
follow
incub
min
c
cell
ad
well
per
well
media
per
well
day
cultiv
c
co
cytopath
effect
cpe
prrsv
evalu
optic
microscopi
reciproc
valu
last
sera
dilut
caus
reduct
cpe
defin
viru
neutral
antibodi
titer
lymphocyt
transform
test
perform
accord
method
publish
earlier
peripher
blood
mononuclear
cell
pbmc
obtain
gradient
centrifug
post
infect
end
experi
frontier
immunolog
wwwfrontiersinorg
sigmaaldrich
concentr
cell
adjust
cell
medium
supplement
autolog
serum
iuml
penicillin
streptomycin
gentamicin
incub
optim
concentr
specif
antigen
moi
day
c
co
neg
control
incub
medium
sampl
evalu
triplic
hthymidin
ad
last
day
cultiv
subsequ
cell
harvest
filterm
harvestor
packard
bioscienc
compani
usa
hthymidin
incorpor
measur
micropl
scintil
luminesc
counter
topcount
nxt
tm
packard
bioscienc
compani
count
per
minut
cpm
result
express
term
stimul
index
si
calcul
ratio
cpm
stimul
sampl
vs
cpm
nonstimul
control
number
produc
cell
calcul
elispot
techniqu
commerci
avail
porcin
elispot
kit
mabtech
use
accord
manufactur
instruct
number
cell
use
test
well
prrsv
use
stimul
antigenspecif
respons
multipl
infect
moi
mitogen
cona
concentr
use
posit
control
cell
without
stimul
use
neg
control
incub
last
h
spot
detect
use
elispot
reader
system
aid
germani
result
recalcul
number
lymphocyt
pbmc
per
well
stimul
prr
viru
moi
h
cultur
pbmc
pellet
primari
monoclon
antibodi
cocktail
contain
clone
wsu
monoclon
antibodi
center
usa
clone
wsu
usa
tcr
clone
wsu
usa
heatinactiv
goat
serum
ad
cell
incub
min
c
rins
twice
cell
wash
solut
goat
antimous
secondari
antibodi
cocktail
dylight
alexa
fluor
ad
cell
incub
anoth
min
c
cell
rins
antibodi
clone
southern
biotech
prestain
alexa
fluor
dye
use
zenon
antibodi
label
kit
invitrogen
ad
cell
incub
rins
twice
fixat
permeabil
subsequ
intracellular
stain
perform
solut
b
intra
stain
kit
dako
cytom
usa
final
rpeconjug
antibodi
clone
abd
serotec
uk
ad
cell
incub
min
cell
measur
soon
possibl
use
bd
lsr
fortessa
flow
cytomet
bectondickinson
usa
least
event
acquir
postacquisit
analysi
data
perform
use
fac
diva
softwar
bectondickinson
usa
follow
lymphocyt
subpopul
identifi
percentag
cell
establish
subpopul
normal
data
distribut
confirm
experiment
group
compar
use
nonparametr
manwhitney
test
data
differ
date
compar
use
nonparametr
wilcoxon
test
pair
sampl
vaccin
inactiv
vaccin
first
igm
serum
start
appear
day
first
dose
piglet
day
second
dose
anim
group
figur
tabl
igg
antibodi
appear
anim
group
day
second
dose
figur
level
antibodi
group
significantli
higher
group
given
vaccin
group
piglet
vaccin
mlv
vaccin
igm
igg
antibodi
appear
day
vaccin
day
immun
antibodi
respons
compar
group
infect
identifi
increas
antibodi
vaccin
group
group
increas
serum
igg
antibodi
observ
week
especi
day
infect
antibodi
level
significantli
exceed
valu
mlv
immun
group
control
one
group
show
sharp
increas
post
infect
day
level
serum
igg
antibodi
interv
compar
group
immun
mlv
serum
igg
level
increas
day
post
infect
reach
group
valu
control
nonimmun
group
first
igm
antibodi
appear
day
infect
signific
increas
day
igg
antibodi
level
appear
day
infect
lower
immun
group
viru
neutral
antibodi
detect
sera
anim
day
vaccin
figur
antibodi
detect
anim
group
end
experi
day
postinfect
high
level
viru
neutral
antibodi
detect
group
except
group
significantli
lower
level
found
figur
local
antibodi
balf
perform
day
post
vaccin
detect
low
level
iga
immun
group
figur
igg
none
level
group
significantli
higher
figur
day
infect
detect
low
level
iga
antibodi
control
group
low
level
igg
antibodi
immun
group
none
local
antibodi
detect
saliva
group
low
concentr
day
second
vaccin
group
infect
variabl
individu
interv
statist
signific
betweengroup
differ
figur
fece
local
antibodi
iga
detect
week
second
immun
dose
group
week
mlv
immun
group
figur
increas
level
antibodi
detect
group
includ
control
infect
statist
signific
betweengroup
differ
posit
cellmedi
respons
lymphocyt
stimul
specif
antigen
vitro
stimul
index
ltt
observ
group
day
post
vaccin
day
postinfect
figur
posit
stimul
index
detect
group
day
post
vaccin
nonspecif
basal
stimul
occur
day
post
vaccin
group
figur
group
immun
inactiv
vaccin
show
mark
nonspecif
stimul
cell
even
without
use
antigen
figur
therefor
imposs
demonstr
effect
antigen
addit
thu
cellmedi
immun
respons
cellmedi
immun
respons
challeng
infect
posit
vaccin
group
control
group
day
post
infect
use
elispot
pbmc
bronchoalveolar
lavag
result
recalcul
number
lymphocyt
differ
individu
anim
signific
differ
group
detect
figur
detect
produc
lymphocyt
prr
antigen
stimul
mark
differ
control
found
partli
also
subset
immun
group
day
infect
group
vaccin
live
vaccin
viru
load
demonstr
serum
saliva
day
immun
balf
day
immun
time
point
lavag
taken
fece
occasion
day
vaccin
piglet
day
immun
data
shown
clinic
sign
observ
piglet
infect
elev
bodi
temperatur
occasion
found
first
day
independ
experiment
group
howev
viral
shed
note
betweengroup
differ
viru
appear
serum
saliva
fece
group
includ
control
group
day
infect
figur
b
viru
detect
balf
day
infect
group
figur
viru
shed
decreas
immun
group
day
infect
level
group
significantli
lower
compar
control
group
day
infect
neg
sampl
appear
day
infect
saliva
group
fece
group
goal
studi
establish
comprehens
immun
respons
characterist
use
sever
methodolog
approach
monitor
dynam
differ
compart
timedepend
manner
vaccin
challeng
infect
compar
immun
respons
differ
kill
modifi
live
vaccin
prr
use
methodolog
tool
order
compar
immun
respons
vaccin
differ
vaccin
use
model
vaccin
young
piglet
begin
week
age
given
vaccin
interv
subsequ
infect
regardless
fact
manufactur
recommend
differ
especi
progressi
paper
publish
provid
comprehens
pictur
immun
respons
vaccin
prrsv
major
exist
studi
base
mainli
evalu
vaccin
effect
monitor
immun
respons
found
blood
result
show
antibodi
immun
infect
viru
infect
detect
monitor
compart
blood
respiratori
tract
intestin
repeat
sampl
simultan
monitor
antibodi
cellmedi
immun
viru
shed
systemat
local
manag
get
comprehens
inform
dynam
immun
respons
vaccin
prr
viru
infect
practic
diagnost
field
sampl
effort
seek
simpl
approach
obtain
tent
inform
epidemiolog
situat
herd
one
current
trend
monitor
antibodi
level
shed
viru
oral
fluid
experi
antibodi
detect
rate
oral
fluid
collect
rope
pen
suffici
level
antibodi
detect
vaccin
low
increas
challeng
infect
find
confirm
possibl
use
approach
preliminari
characterist
herd
interest
observ
dynam
antibodi
level
viral
shed
fece
approach
often
use
prrsv
infect
monitor
use
situat
fece
sampl
readili
avail
sampl
sourc
wonder
among
thing
extent
infect
occur
system
local
respiratori
tract
occur
remot
compart
find
show
fecal
sampl
also
use
prrsv
infect
monitor
detect
virus
antibodi
entir
consist
appear
individu
anim
ceas
later
interv
therefor
necessari
consid
find
approxim
use
herdor
penlevel
test
establish
diagnosi
individu
anim
appear
technic
difficult
demonstr
specif
cellmedi
immun
partial
result
provid
three
method
use
comprehens
pictur
could
obtain
compil
inform
therefor
possibl
use
data
product
elispot
although
current
commonli
use
method
cmi
posit
cellmedi
respons
lymphocyt
stimul
specif
antigen
vitro
lymphocyt
transform
test
observ
mlv
group
especi
group
nonspecif
basal
stimul
occur
day
postvaccin
group
strong
nonspecif
stimul
pbmc
without
specif
antigen
detect
group
immun
inact
type
vaccin
nonspecif
stimul
cell
vivo
mask
overal
pictur
thu
specif
cellmedi
immun
demonstr
effect
attribut
use
strong
adjuv
inactiv
type
vaccin
test
product
detect
elispot
often
use
identifi
cmi
experiment
studi
field
shown
increas
blood
cell
acquir
lavag
individu
variabl
among
anim
high
consequ
differ
found
group
studi
detect
also
produc
lymphocyt
prr
antigen
stimul
immun
group
day
infect
mark
differ
control
found
partli
also
subset
lymphocyt
subpopul
belong
cytotox
group
cell
consid
group
memori
cell
anoth
studi
express
cytotox
describ
help
recov
prr
infect
qualit
quantit
differ
immun
respons
inactiv
vaccin
mlv
one
immun
inactiv
vaccin
especi
high
level
antibodi
produc
gener
serum
mostli
igm
igg
isotyp
also
local
saliva
balf
igg
iga
nevertheless
note
appli
progressi
piglet
studi
manufactur
declar
use
vaccin
gilt
sow
cellmedi
immun
detect
infect
high
nonspecif
cell
stimul
detect
vaccin
therefor
specif
respons
could
demonstr
interv
antigen
specif
cell
mediat
immun
inactiv
vaccin
rare
describ
work
describ
low
cmi
vaccin
inactiv
vaccin
immun
mlv
vaccin
suffici
level
antibodi
serum
balf
igg
also
produc
lower
inactiv
vaccin
administr
level
iga
antibodi
balf
compar
low
low
level
viru
neutral
antibodi
vaccin
explain
short
interv
vaccin
infect
sinc
neutral
antibodi
vaccin
prr
infect
occur
within
day
dynam
viru
shed
vaccin
infect
often
use
monitor
vaccin
efficaci
decreas
viru
secret
observ
day
mlv
immun
disappear
day
anoth
studi
excret
viru
describ
still
day
vaccin
porcili
amervac
vaccin
demonstr
cellmedi
immun
reduct
viral
load
correl
studi
author
support
prefer
use
mlv
vaccin
control
prr
infect
question
extent
result
influenc
composit
vaccin
differ
manufactur
extent
differ
type
vaccin
inactiv
vs
live
attenu
obviou
differ
qualiti
inactiv
vaccin
wherea
charact
immun
respons
mlv
vaccin
similar
partial
differ
timerel
respons
dynam
vaccin
amervac
show
pronounc
decreas
viru
secret
tendenc
induc
steril
immun
porcili
vaccin
pronounc
cmi
lymphocyt
transform
test
note
strain
use
porcili
higher
genet
link
lelystad
strain
compar
strain
amervac
howev
probabl
significantli
affect
characterist
despit
fact
mani
studi
focus
prr
immunoprophylaxi
alreadi
publish
mani
procedur
implement
agricultur
industri
univers
model
yet
exist
use
live
attenu
vaccin
gener
prefer
also
confirm
field
studi
studi
control
infect
repeat
blanket
immun
mlv
vaccin
porcili
follow
target
immun
gilt
sow
success
strategi
select
evid
viru
erad
given
herd
demonstr
introduc
sentinel
anim
fatten
herd
base
result
believ
control
program
adopt
even
herd
continu
throughput
hous
without
interrupt
product
howev
case
vaccin
one
necessari
precondit
introduct
strict
principl
good
biosecur
less
import
use
anim
approv
branch
commiss
anim
welfar
ministri
agricultur
czech
republ
approv
protocol
mze
part
project
part
project
respig
mt
vc
js
mf
design
studi
mt
js
kn
perform
experi
hk
lk
po
jf
perform
lab
work
analyz
data
lk
produc
figur
statist
analysi
mt
wrote
manuscript
js
mf
particip
manuscript
prepar
author
read
approv
final
manuscript
studi
support
project
ministri
agricultur
czech
republ
project
financi
support
ministri
educ
youth
sport
czech
republ
npu
program
